Literature DB >> 3500677

Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus.

M A Byron1, M J Allington, H M Chapel, A G Mowat, S A Cederholm-Williams.   

Abstract

Fibrinolytic and other factors have been measured in 73 patients with systemic lupus erythematosus or related conditions to determine whether clinical thrombosis, a common feature of these disorders, is associated with defective fibrinolysis. Twenty five of 72 (35%) patients, compared with two of 22 (9%) controls, showed a low level of plasminogen activator activity in response to venous occlusion, suggesting decreased fibrinolytic potential. In addition, mean plasma levels of von Willebrand factor antigen and fibronectin were markedly raised in the patients (mean (SD) 384.5 (277)% and 727 (436) mg/l respectively) compared with healthy controls (100 (50)% and 306 (65) mg/l). These data suggest a degree of endothelial cell dysfunction. No clear correlation was found between a history of thrombosis and any plasma factor measured, except for prolongation of clotting tests suggestive of the 'lupus anticoagulant'.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500677      PMCID: PMC1003380          DOI: 10.1136/ard.46.10.741

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  22 in total

1.  Report of the Working Party on Acquired Inhibitors of Coagulation: studies of the "lupus" anticoagulant.

Authors:  D Green; C Hougie; F J Kazmier; K Lechner; P M Mannucci; C R Rizza; Y Sultan
Journal:  Thromb Haemost       Date:  1983-04-28       Impact factor: 5.249

2.  Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance.

Authors:  K S Kant; V E Pollak; M A Weiss; H I Glueck; A N Miller; E V Hess
Journal:  Medicine (Baltimore)       Date:  1981-03       Impact factor: 1.889

3.  Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications.

Authors:  J L Wautier; R C Paton; M P Wautier; D Pintigny; E Abadie; P Passa; J P Caen
Journal:  N Engl J Med       Date:  1981-07-30       Impact factor: 91.245

4.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

5.  Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.

Authors:  P Glas-Greenwalt; K S Kant; C Allen; V E Pollak
Journal:  J Lab Clin Med       Date:  1984-12

6.  Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant.

Authors:  M L Boey; C B Colaco; A E Gharavi; K B Elkon; S Loizou; G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-08

7.  Hypercoagulability and coronary artery disease.

Authors:  N T O'Connor; S Cederholm-Williams; S Copper; L Cotter
Journal:  Br Heart J       Date:  1984-12

8.  Plasma haemostatic factors and diabetic retinopathy.

Authors:  T L Dornan; I L Rhymes; S A Cederholm-Williams; C R Rizza; M B Pepys; A J Bron; R C Turner
Journal:  Eur J Clin Invest       Date:  1983-06       Impact factor: 4.686

Review 9.  The clotting defect in SLE.

Authors:  M A Byron
Journal:  Clin Rheum Dis       Date:  1982-04

10.  Abnormal endothelial release of fibrinolytic activity and fibronectin in diabetic microangiopathy.

Authors:  B Haitas; A J Barnes; S A Cederholm-Williams; J Moore; M E Shogry; R C Turner
Journal:  Diabetologia       Date:  1984-11       Impact factor: 10.122

View more
  10 in total

1.  Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.

Authors:  A Uddhammar; S Rantapåå-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

Review 2.  The antiphospholipid antibody dilemma.

Authors:  R H Derksen; P Hasselaar; J D Oosting; P G De Groot
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

3.  Blood pressure and vascular dysfunction underlie elevated cerebral blood flow in systemic lupus erythematosus.

Authors:  Charles Gasparovic; Clifford Qualls; Ernest R Greene; Wilmer L Sibbitt; Carlos A Roldan
Journal:  J Rheumatol       Date:  2012-01-15       Impact factor: 4.666

4.  Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus.

Authors:  A J MacGregor; V B Dhillon; A Binder; C A Forte; B C Knight; D J Betteridge; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 5.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

6.  Risk factors for thrombosis in lupus patients.

Authors:  P Hasselaar; R H Derksen; L Blokzijl; M Hessing; H K Nieuwenhuis; B N Bouma; P G De Groot
Journal:  Ann Rheum Dis       Date:  1989-11       Impact factor: 19.103

7.  Fibrinolysis and coagulation abnormalities in systemic lupus erythematosus. Relationship with Raynaud's phenomenon, disease activity, inflammatory indices, anticardiolipin antibodies and corticosteroid therapy.

Authors:  A Doria; A Ghirardello; M Boscaro; M L Viero; E Vaccaro; G M Patrassi; P F Gambari
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

Review 8.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

9.  Endothelial cell binding by human polyclonal anti-DNA antibodies: relationship to disease activity and endothelial functional alterations.

Authors:  T M Chan; P M Yu; K L Tsang; I K Cheng
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

10.  Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis.

Authors:  Ling Qin; Samantha Stanley; Huihua Ding; Ting Zhang; Van Thi Thanh Truong; Teja Celhar; Anna-Marie Fairhurst; Claudia Pedroza; Michelle Petri; Ramesh Saxena; Chandra Mohan
Journal:  Arthritis Res Ther       Date:  2019-07-18       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.